MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Psychosis"

  • 2022 International Congress

    Epidemiologic And Clinical Features Of Psychiatric Disorders In Patients With Parkinson’s Disease – A Retrospective Cohort Study

    O. Koniashvili, G. Khachiashvili, L. Gabunia (Tbilisi, Georgia)

    Objective: We aimed to assess the average duration of Parkinson's disease at the time patient was diagnosed with specific neuropsychiatric disturbance, to study their prevalence…
  • 2022 International Congress

    Non-Invasive Brain Stimulation for the Treatment of Psychiatric Symptoms in Parkinson’s Disease: A Systematic Review and Meta-analysis

    Y. Qu (Wuhan, China)

    Objective: This meta-analysis aims to assess the effect of NIBS technique for psychiatric symptoms in patients with PD. Background: Non-invasive brain stimulations (NIBS), especially repetitive…
  • 2022 International Congress

    ER Visits and Hospitalizations Among Patients Treated with Pimavanserin or Other-AAPs for Parkinson’s Disease Psychosis: Analysis of Medicare beneficiaries

    S. Kumar, N. Rashid, D. Doshi, K. Rajagopalan (Dover, USA)

    Objective: To examine health resource utilization (HRU) outcomes among PDP patients treated with PIMA vs. other AAPs. Background: Real-world analysis demonstrating pimavanserin (PIMA) benefits, the…
  • 2022 International Congress

    Parkinson’s Disease, Cognition, Positive Symptoms and Medication Management

    O. Kaczmarek, S. Baek, A. Sethi, A. Stolarczyk, B. Bumstead, M. Buhse, M. Zarif, B. Anand, M. Gudesblatt (Patchogue, USA)

    Objective: Explore the relationship between multi-domain cognitive testing and patient-reported psychiatric symptoms in PwPD to self-medication management capabilities. Background: Parkinson’s disease (PD) is a complex…
  • 2022 International Congress

    Phantom boarder syndrome associated with experimentally-induced presence hallucinations in Parkinson’s disease

    J. Potheegadoo, F. Bernasconi, O. Blanke (Geneva, Switzerland)

    Objective: Measuring experimentally-induced presence hallucinations in patients with Parkinson’s disease phantom boarder phenomena. Background: Phantom boarder syndrome (PB) is described as the sensation that someone…
  • 2022 International Congress

    Reduced Risk of Mortality and Antipsychotics in Parkinson’s Disease-Related Psychosis: Pimavanserin vs Off-Label Antipsychotics

    S. Isaacson, F. Pagan, D. Truong, V. Abler, R. Pahwa (Boca Raton, USA)

    Objective: Summarize the available data for the mortality risk associated with Parkinson’s disease (PD) psychosis (PDP) and pimavanserin. Background: PDP is associated with increased mortality…
  • MDS Virtual Congress 2021

    Fatal Psychosis in a young Girl

    D. Joshi, M. Tapadia, K. Bismaya, A. Kumar (Varanasi, India)

    Objective: We describe a 24-year young female who presented to us with features of Neurolept malignant syndrome.  She was later evaluated and found to have…
  • MDS Virtual Congress 2021

    Effect of the GlyT1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset

    I. Frouni, SG. Nuara, D. Bédard, A. Hamadjida, JC. Gourdon, P. Huot (Montreal, Canada)

    Objective: To determine the effect of glycine transporter 1 (GlyT1) inhibition with ALX-5407 on dyskinesia, psychosis-like behaviours (PLBs) and parkinsonism severity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned…
  • MDS Virtual Congress 2021

    Effect of simultaneous mGlu2 positive allosteric modulation and orthosteric stimulation combined with 5-HT2A antagonism on psychosis-like behaviours, dyskinesia and parkinsonism in the MPTP-lesioned marmoset

    S. Nuara, J. Gourdon, P. Huot (Montreal, Canada)

    Objective: To assess the effects of concurrent metabotropic glutamate type 2 (mGlu2) positive allosteric modulation and orthosteric stimulation combined with serotonin type 2A (5-HT2A) antagonism.…
  • MDS Virtual Congress 2021

    Neuropsychiatric Issues in Parkinson’s Disease

    F. Aziouaz, Y. Mebrouk (Oujda, Morocco)

    Objective: The aim of this study is to analyze the epidemiology, clinical features and treatment approaches for NPS in PD. Background: Parkinson's disease (PD) is…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 14
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley